Coherus Oncology, Inc.: financing cash flow
Financing cash flow for Coherus Oncology, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Coherus Oncology, Inc. financial histories
What this measure means
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
Exact concept: us-gaap:NetCashProvidedByUsedInFinancingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -273,705,000 | USD | 2026-03-09 | 10-K · 0001104659-26-025308 |
| 2024-01-01 | 2024-12-31 | -186,974,000 | USD | 2026-03-09 | 10-K · 0001104659-26-025308 |
| 2023-01-01 | 2023-12-31 | 69,600,000 | USD | 2025-03-17 | 10-K · 0001558370-25-003126 |
| 2022-01-01 | 2022-12-31 | 54,326,000 | USD | 2025-03-17 | 10-K · 0001558370-25-003126 |
| 2021-01-01 | 2021-12-31 | 51,879,000 | USD | 2024-03-15 | 10-K · 0001558370-24-003436 |
| 2020-01-01 | 2020-12-31 | 223,946,000 | USD | 2023-03-06 | 10-K · 0001558370-23-002917 |
| 2019-01-01 | 2019-12-31 | 89,370,000 | USD | 2022-02-23 | 10-K · 0001558370-22-001764 |
| 2018-01-01 | 2018-12-31 | 105,421,000 | USD | 2021-02-25 | 10-K · 0001558370-21-001829 |
| 2017-01-01 | 2017-12-31 | 206,787,000 | USD | 2020-02-27 | 10-K · 0001564590-20-007416 |
| 2016-01-01 | 2016-12-31 | 226,179,000 | USD | 2019-02-28 | 10-K · 0001564590-19-005470 |
Related financial histories
- Coherus Oncology, Inc.: total assets
- Coherus Oncology, Inc.: total liabilities
- Coherus Oncology, Inc.: stockholders equity
- Coherus Oncology, Inc.: cash and cash equivalents
- Coherus Oncology, Inc.: net income or loss
- Coherus Oncology, Inc.: operating cash flow
- Coherus Oncology, Inc.: capital expenditure payments
- Coherus Oncology, Inc.: revenue
- Coherus Oncology, Inc.: contract revenue excluding tax
- Coherus Oncology, Inc.: investing cash flow
- Coherus Oncology, Inc.: retained earnings or deficit
- Coherus Oncology, Inc.: basic weighted-average shares
- Coherus Oncology, Inc.: diluted weighted-average shares
- Coherus Oncology, Inc.: basic earnings per share
- Coherus Oncology, Inc.: diluted earnings per share
- Coherus Oncology, Inc.: income tax expense or benefit
- Coherus Oncology, Inc.: net property, plant and equipment
- Coherus Oncology, Inc.: share-based compensation expense
- Coherus Oncology, Inc.: operating income or loss
- Coherus Oncology, Inc.: current assets
- Coherus Oncology, Inc.: interest expense
- Coherus Oncology, Inc.: current liabilities
- Coherus Oncology, Inc.: current accounts payable
- Coherus Oncology, Inc.: goodwill carrying amount
- Coherus Oncology, Inc.: net finite-lived intangible assets
- Coherus Oncology, Inc.: net current accounts receivable
- Coherus Oncology, Inc.: operating expenses
- Coherus Oncology, Inc.: net inventory
- Coherus Oncology, Inc.: selling, general and administrative expense
- Coherus Oncology, Inc.: research and development expense
Inspect the source
- Entity
- Coherus Oncology, Inc. / CIK 0001512762
- Captured
- 2026-09-20T09:13:09.943Z
- SEC response SHA-256
5c5765981b2a86ba6afe797bbe14b15cb57f0db8164b0eb431640837c7af90f8
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001512762.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))